Please cite this article in press Ramanjeet Kaur et al., A Review: Initial Risk Factors Of Hypertension And Diabetes Mellitus.., Indo Am. J. P. Sci, 2021; 08(08).

1. WHO (2008) Causes of death and global burden of disease.
2. Arambewela, M. H., Somasundaram, N. P., Jayasekara, H. B. P. R., Kumbukage, M. P., Jayasena, P. M. S., Chandrasekara, C. M. P. H., … &Kusumsiri, D. P. (2018). Prevalence of chronic complications, their risk factors, and the cardiovascular risk factors among patients with type 2 diabetes attending the diabetic clinic at a Tertiary Care Hospital in Sri Lanka. Journal of diabetes research, 2018.
3. D. R. Whiting, L. Guariguata, C. Weil, and J. Shaw, “IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030,” Diabetes Research and Clinical Practice, vol. 94, no. 3, pp. 311–321, 2011
4. Unadike, B. C., Eregie, A., &Ohwovoriole, A. E. (2011). Prevalence of hypertension amongst persons with diabetes mellitus in Benin City, Nigeria. Nigerian journal of clinical practice, 14(3), 300-302.
5. Colosia, A. D., Palencia, R., & Khan, S. (2013). Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review. Diabetes, metabolic syndrome and obesity: targets and therapy, 6, 327.
6. Landsberg L, Molitch M. Diabetes and hypertension: pathogenesis, prevention and treatment. Clin Exp Hypertens. 2004;26:621–8.
7. J. R. Sowers and S. Khoury, “Diabetes and hypertension: a review,” Primary Care, vol. 18, no. 3, pp. 509–524, 1991.
8. Cheung BM. The hypertension-diabetes continuum. J Cardiovasc Pharmacol. 2010; 55: 333–9. This is a brief review of the overlap between hypertension and type 2 diabetes that proposes there is a spectrum ranging from hypertension without dysglycemia to type2 diabetes without elevated blood pressure.
9. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol. 2004;286:H1597–1602.
10. Davy KP, Hall JE. Obesity and hypertension: two epidemics or one? Am J PhysiolRegulIntegr Comp Physiol. 2004;286:R803– 813.
11. He YH, Jiang GX, Yang Y, et al. Obesity and its associations with hypertension and type 2 diabetes among Chinese adults age 40 years and over. Nutrition. 2009; 25: 1143–9.
12. Loos RJ, Bouchard C. Obesity–is it a genetic disorder? J Intern Med. 2003;254:401–25
13. Maes HH, Neale MC, Eaves LJ. Genetic and environmental factors in relative body weight and human adiposity. Behav Genet. 1997;27:325–51.
14. Saunders CL, Chiodini BD, Sham P, et al. Meta-analysis of genome-wide linkage studies in BMI and obesity. Obesity (Silver Spring). 2007;15:2263–75.
15. Wang K, Li WD, Zhang CK, et al. A genome-wide association study on obesity and obesity-related traits. PLoS One. 2011;6: e18939.
16. Cheung CY, Tso AW, Cheung BM, et al. Obesity susceptibility genetic variants identified from recent genome-wide association studies: implications in a chinese population. J Clin Endocrinol Metab. 2010;95:1395–403.
17. Wang T, Huang Y, Xiao XH, et al. The association between common genetic variation in the FTO gene and metabolic syndrome in Han Chinese. Chin Med J (Engl). 2010;123:1852–8.
18. Wing MR, Ziegler JM, Langefeld CD, et al. Analysis of FTO gene variants with obesity and glucose homeostasis measures in the multiethnic Insulin Resistance Atherosclerosis Study cohort. Int J Obes (Lond). 2010.
19. Ng MC, Tam CH, So WY, et al. Implication of genetic variants near NEGR1, SEC16B, TMEM18, ETV5/DGKG, GNPDA2, LIN7C/BDNF, MTCH2, BCDIN3D/FAIM2, SH2B1, FTO, MC4R, and KCTD15 with obesity and type 2 diabetes in 7705 Chinese. J Clin Endocrinol Metab. 2010;95:2418–25.
20. Morimoto K, Morikawa M, Kimura H, et al. Mental stress induces sustained elevation of blood pressure and lipid peroxidation in postmenopausal women. Life Sci. 2008;82:99–107.
21. Pickering TG. Mental stress as a causal factor in the development of hypertension and cardiovascular disease. CurrHypertens Rep. 2001;3:249–54.
22. Esler M, Eikelis N, Schlaich M, et al. Chronic mental stress is a cause of essential hypertension: presence of biological markers of stress. Clin Exp Pharmacol Physiol. 2008;35:498–502.
23. Soucek M, Kara T. Stress-induced hypertension and diabetes mellitus. Vnitr Lek. 2001;47:315–9
24. Seematter G, Guenat E, Schneiter P, et al. Effects of mental stress on insulin-mediated glucose metabolism and energy expenditure in lean and obese women. Am J Physiol Endocrinol Metab. 2000;279:E799–805.
25. Schnall PL, Pieper C, Schwartz JE, et al. The relationship between job strain, workplace diastolic blood-pressure, and leftventricular mass index – results of a case-control study. Jama-J Am Med Assoc. 1990;263:1929–35.
26. Savoia C, Schiffrin EL. Inflammation in hypertension. CurrOpin Nephrol Hypertens. 2006;15:152–8.
27. Stehouwer CD, Gall MA, Twisk JW, et al. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes. 2002;51:1157–65.
28. Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999;340:115–26.
29. Tracy RP. Emerging relationships of inflammation, cardiovascular disease and chronic diseases of aging. Int J ObesRelatMetabDisord. 2003;27 Suppl 3:S29–34.
30. Tracy RP. Inflammation, the metabolic syndrome and cardiovascular risk. Int J Clin Pract Suppl. 2003;134:10–17.
31. Blake GJ, Rifai N, Buring JE, et al. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation. 2003;108:2993–9.
32. Sesso HD, Buring JE, Rifai N, et al. C-reactive protein and the risk of developing hypertension. JAMA. 2003;290:2945–51.
33. Savoia C, Schiffrin EL. Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci. 2007;112:375–84.
34. Witkowska AM. Soluble ICAM-1: a marker of vascular inflammation and lifestyle. Cytokine. 2005;31:127–34
35. Jesmin J, Rashid MS, Jamil H, et al. Gene regulatory network reveals oxidative stress as the underlying molecular mechanism of type 2 diabetes and hypertension. BMC Med Genomics. 2010;3:45.
36. Tsuchida A, Yamauchi T, Takekawa S, et al. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes. 2005;54:3358–70.
37. Yki-Järvinen H. Nonglycemic effects of insulin. Clin Cornerstone. 2003; Suppl 4: S6-12.
38. Jellinger PS. Metabolic consequences of hyperglycemia and insulin resistance. Clin Cornerstone. 2007;8 Suppl 7:S30–42.
39. Deedwania P. Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating beta-blockers. J Clin Hypertens (Greenwich). 2011;13:52–9.
40. Reaven GM. Relationships among insulin resistance, type 2 diabetes, essential hypertension, and cardiovascular disease: similarities and differences. J Clin Hypertens (Greenwich). 2011;13:238–43.
41. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537–44.
42. Parker ED, Schmitz KH, Jacobs Jr DR, et al. Physical activity in young adults and incident hypertension over 15 years of followup: the CARDIA study. Am J Public Health. 2007;97:703–9
43. Cederholm J, Wibell L. The relationship of blood pressure to blood glucose and physical leisure time activity. A study of hypertension in a survey of middle-aged subjects in Uppsala 1981-82. Acta Med Scand. 1986;219:37–46.